sunitinib

The patient was managed by transurethral resection of bladder tumor (TURBT) followed by targeted therapy with sunitinib (37.5 mg)...ccRCC can metastasize to unusual sites, including the urinary bladder. Early recognition through comprehensive imaging and immunohistochemical evaluation is essential for timely diagnosis and management.

After receiving targeted combination immunotherapy with sequential PD-1 inhibitors (toripalimab) plus anti-angiogenic agents (sunitinib, axitinib)-a regimen that enhances anti-tumor immunity but may disrupt pulmonary immune homeostasis-the patient gradually developed progressive dyspnea, chest tightness, hypoxemia, and anuria. Although PJP complicated by hydropneumothorax after immunotherapy is rare, it should be considered as a possible etiology when cancer patients develop progressive dyspnea with difficulty maintaining oxygen saturation after receiving immune checkpoint inhibitor-based therapy, particularly in the context of immune checkpoint inhibitor use. While biomarkers for predicting immunotherapy efficacy and irAEs are well-studied, the identification of specific biomarkers for predicting opportunistic infections like PJP in this context remains an area of active research.

However, the metastatic RCC progressed after another 3 months, and the patient received two lines of tyrosine kinase inhibitors (sunitinib and cabozantinib)...Severe cerebral vasculitis requires hospitalization with prompt diagnostic workup and immunosuppressive treatment. Despite the preterm permanent discontinuation of immunotherapy, the patients can benefit from the systemic treatment.

P2, N=100, Recruiting, National Cancer Institute (NCI) | Trial completion date: Apr 2026 --> Apr 2029 | Trial primary completion date: Apr 2026 --> Apr 2029

Molecular profiling leveraged IMmotion151 (A Study of Atezolizumab in Combination With Bevacizumab Versus Sunitinib in Participants With Untreated Advanced Renal Cell Carcinoma) trial data with whole-exome sequencing, RNA sequencing, and programmed cell death ligand 1 immunohistochemistry. Systemic standard of care treatments for mRCC, which include vascular endothelial growth factor receptor targeted therapy (VEGF-TT [sunitinib or pazopanib]), immune-oncology-VEGF (IO-VE [pembrolizumab and axitinib, pembrolizumab and lenvatinib, nivolumab and cabozantinib, or avelumab and axitinib]), and 2 IO (IO-IO [ipilimumab and nivolumab]) regimens...In this cohort study, the very favorable risk subgroup had a less immunogenic molecular profile and superior outcomes from VEGF-containing regimens (VEGF-TT and IO-VE) compared with the favorable risk group. The IO-IO combination showed significantly worse survival in this population, suggesting that VEGF inhibition remains essential for optimal outcomes.

P=N/A, N=6, Terminated, University Hospital, Rouen | N=64 --> 6 | Not yet recruiting --> Terminated; Changes in the indication for Sunitinib in metastatic renal cell carcinoma, which have led to a significant decrease in its use in the urology department. Collected data will not be sufficient to perform a statistical analysis.

Genetic studies identify SLC7A11 as a critical mediator: its knockdown sensitizes cells to the combination, while its overexpression confers resistance. These findings establish a novel ferroptosis-based mechanism for the PTX/SUN synergy, positioning SLC7A11 as a key determinant of therapeutic response and providing a rationale for targeting this pathway in lung cancer.

Together, these findings highlight the potential role of extrahepatic CYP2U1 in the local metabolism of tyrosine kinase inhibitors and suggest that CYP2U1-mediated transformations directly influence antitumor efficacy at thymic tumor sites. SIGNIFICANCE STATEMENT: Understanding the interactions between cytochrome P450 2U1 and cytochrome P450 2D6 in nanodiscs and thymus tumor-targeting drugs, sorafenib and sunitinib, led to discovery of new bioactive metabolites that carry differential anticancer properties compared with their parent compounds.

P2, N=48, Recruiting, Asan Medical Center | Trial completion date: Dec 2026 --> Dec 2027 | Trial primary completion date: Aug 2026 --> Aug 2027

P2, N=28, Recruiting, Asan Medical Center | Not yet recruiting --> Recruiting

P2, N=40, Completed, Asan Medical Center | Recruiting --> Completed

P3, N=450, Recruiting, GlaxoSmithKline